IN THE CLAIMS

1. (Twice Amended) A sustained release ophthalmic pharmaceutical composition in the form of an aqueous gel, a pourable aqueous dispersion, or anhydrous salt, for controlling and lowering intraocular pressure comprising:

a therapeutically effective amount of a beta blocker of the formula:

 R^1 -O-CH₂-CH(OH)-CH₂-NR²R³

wherein ${\sf R}^1$ is a substituted or unsubstituted cyclic or aliphatic moiety, and ${\sf R}^2$ and ${\sf R}^3$ are independently selected from H and substituted and unsubstituted alkyl;

an amount of an anionic mucomimetic polymer having carboxylic acid functional groups which comprise from 2 to 7 carbon atoms per functional group and a molecular weight of from 50,000 to 6 million such that the composition in the form of an aqueous gel or pourable aqueous dispersion has a viscosity of about 1 to about 20,000 cps.; and a particulate cation exchange resin at a concentration of from about 0.05% to 10.0% by weight, the composition having a pH of from about 3.0 to 8.5.

7. (Twice Amended) A method of treatment for controlling and lowering intraocular pressure which comprises administering topically to the affected eye a pharmaceutical composition which includes:

a therapeutically effective amount of a beta blocker of the formula:

 R^{1} -0-CH₂-CH(OH)-CH₂-NR²R³

wherein R^1 is a substituted or unsubstituted cyclic or aliphatic moiety, and R^2 and R^3 are independently selected from H and substituted and unsubstituted alkyl;

an amount of an anionic mucomimetic polymer having carboxylic acid functional groups which comprise from 2 to 7 carbon atoms per functional group and a molecular weight of from 50,000 to 6 million such that the composition in the form of an aqueous gel or pourable aqueous dispersion has a viscosity of about 1 to about 20,000 cps.; and a particulate cation exchange resin at a concentration of from about 0.05% to 10.0% by weight, the composition having a pH of from about 3.0 to 8.5.

Please add dependent claims 23 and 24.

23. The composition of claim 1 wherein the particulate cation exchange resin is in the form of a finely divided powder, said powder consisting of spheroidal particles.

The method of claim 7 wherein the particulate cation exchange resin is in the form of a finely divided powder, said powder consisting of spheroidal particles.

FIRM

 $\frac{3}{3}$

(2)

(3